Ultime notizie per Altimmune (NASDAQ:ALT) Azioni

Altimmune

Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

Altimmune Inc

AltLayer - United States Dollar

ALT11M2507 - United States Dollar

ALT2612 - United States Dollar

Morella Corp Ltd

ALPINE AUTO BROKERS INC by Alpine Auto Brokers Inc

Alpine Auto Brokers Inc

ALTURAS MINERALS CORP by Alturas Minerals Corp.

Alturas Minerals Corp

ALTITUDE INTL INC by Altitude International Holdings, Inc.

Altitude International Holdings Inc

Altitude Acquisition Corp. II

Alta Equipment Group Inc. Class A Common Stock

Alta Equipment Group Inc

Alta Equipment Group Inc. Depositary Shares (each representing 1/1000th in a share of 10% Series A Cumulative Perpetual Preferred Stock)

ALTECH CHEMICALS LTD by Altech Chemicals Ltd.

Altech Batteries Ltd

AlTi Global Inc

Pacer Lunt Large Cap Alternator ETF

Arcadium Lithium PLC

Kinetik Holdings Inc Warrants (09/11/2023)

ALTERNUS ENERGY GROUP PLC by ALTERNUS ENERGY GROUP PLC.

Alternus Energy Group PLC

Alto Ingredients Inc

Altamont Pharma Acquisition Corp

ALTIPLANO METALS INC ORD by Altiplano Metals Inc.

Altiplano Metals Inc

Altair Engineering Inc. - Class A Common Stock

Altair Engineering Inc

ALTAIR ENGINEERING CL A ORD

ALT5 Sigma Corp

Altitude Acquisition Corp. III

Altitude Acquisition Corp Ordinary Shares - Class A

Altitude Acquisition Corp

Altitude Acquisition Corp Units (1 Ord Share Class A & 1/2 War)

Altitude Acquisition Corp Warrants (30/11/2027)

ALTEX INDUS INC by Altex Industries, Inc.

Altex Industries Inc

Global X Alternative Income ETF

<a href="https://www.globenewswire.com/Tracker?data=gn2ovBju6Frioeal4FWhYyaxaJz-S4EnlwGwo1RdtQAm_BVGEgZMa4Dyyp5jZjcvkSZ53kFs_DlYMRe89QD4Qw==">Altimmune, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), a clinical-stage biopharmaceutical company, today announced that new data showing reductions of multiple classes of atherogenic and cardio-inflammatory lipids in subjects treated with pemvidutide will be presented in a poster session at The Liver Meeting&#xAE; 2024 of the American Association for the Study of Liver Diseases (AASLD) in San Diego, CA taking place November 15-19, 2024. The data were derived from Altimmune's 12-week Phase 1b randomized, placebo-controlled study in subjects with metabolic dysfunction-associated steatotic liver disease (MASLD), a precursor to the more serious metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed enrollment in a Phase 2b efficacy trial of pemvidutide in patients with biopsy-confirmed F2/F3 MASH, with topline data expected in the second quarter of 2025.

Biotech

News

General

Altimmune To Present New Data On The Lipidomic Profile In Subjects Treated With Pemvidutide At The Liver Meeting 2024

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) and Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) have dominated the obesity drug market with their leading therapies, Wegovy and Zepbound, but the next generation of treatments could shift this dynamic.
These new drugs, expected to hit the market by 2029, aim to surpass current efficacy levels while offering more convenient dosing options, such as oral and monthly injections. This shift, driven by innovation and competition, could change the market landscape despite Novo and Lilly&#8217;s current hold on the sector.
According to a <a target="_blank" href="https://assets.contentstack.io/v3/assets/blt4eb669caa7dc65b2/blt79266ca5d3a390c1/Obesity_Drug_Market_Report.pdf" rel="noreferrer noopener">report</a> by Morningstar, the global GLP-1 market is poised to reach $200 billion by 2031, with obesity treatment expected to account for 68% of sales.
While Novo Nordisk and Eli Lilly are projected to retain two-thirds of this market, driven by first-mover advantage and robust pipelines, new competitors could claim significant market share.
Public and private biopharma firms are increasingly focusing on cardiometabolic drug development, with 16 new obesity drugs potentially launching by 2029 the report added.
This pipeline includes candidates from major players such as <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40422774/roche-misses-out-on-weight-loss-blockbuster-drug-now-playing-catch-up-in-booming-market" rel="noreferrer noopener">Roche Holdings AG</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>), Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), and private companies like Boehringer Ingelheim.
Roche released topline results from the ongoing multi-part Phase 1 trial for CT-996, showing data better compared <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39817857/obesity-drugs-focused-stocks-tumble-on-wednesday-whats-going-on-with-eli-lilly-novo-nordisk-vikin" rel="noreferrer noopener">to existing competitors</a>. Despite Novo Nordisk and Eli Lilly&#8217;s strong market positions, some analysts view their stocks as overvalued.
Achieving the market penetration needed to justify their current valuations would require near-unprecedented success, including capturing 75% of the U.S. obesity market and 95% of the global market by 2031.
Additionally, maintaining stable pricing seems unlikely, with increased competition and innovation expected to put downward pressure on drug prices.
Supply chain issues pose further challenges. Both companies face difficulties in manufacturing peptide-based drugs at scale, such as Wegovy and Zepbound.
While oral peptide drugs like high-dose Novo Nordisk&#8217;s Rybelsus and Viking Therapeutics Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37937068/viking-therapeutics-investigational-oral-obesity-drug-shows-reduced-weight-in-small-study" rel="noreferrer noopener">VK2735 offer alternatives</a>, they may be even harder to supply due to the higher doses required for efficacy.
Small molecule drugs, like Lilly&#8217;s orforglipron and Pfizer&#8217;s<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39753273/with-oral-anti-obesity-candidate-development-pfizer-seeks-relevant-and-competitive-" rel="noreferrer noopener"> danuglipron</a>, offer the best potential for scalable production, promising more streamlined manufacturing processes.
New entrants to the obesity drug market are pushing the envelope, with drug candidates from companies like Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), Altimmune Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>), and Zealand Pharma (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZLDPF#OTC">ZLDPF</a>) on the horizon.
In a phase 1 study, Amgen&#8217;s AMG 133 showed an acceptable safety and tolerability profile and pronounced <a target="_blank" href="https://www.benzinga.com/general/biotech/24/02/36934096/weight-loss-drugs-new-entrant-amgen-to-compete-with-novo-nordisk-eli-lilly-as-investigational-wei" rel="noreferrer noopener">dose-dependent weight loss</a>.&nbsp;
Altimmune said the body composition study of pemvidutide showed preservation of lean mass, with 25.5% of weight loss derived from lean mass and 74.5% <a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37958653/why-is-obesity-drug-developer-altimmune-stock-trading-lower-on-wednesday" rel="noreferrer noopener">from adipose tissue</a>.
These next-generation drugs could challenge the dominance of Novo and Lilly, especially if they offer better efficacy or fewer side effects.
However, Wegovy and Zepbound&#8217;s entrenched positions and ongoing innovation may keep Novo and Lilly at the forefront for the foreseeable future.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41295498/gsk-settles-majority-of-zantac-lawsuits-but-pipeline-doubts-remain" target="_blank" rel="noreferrer noopener">GSK Settles Majority Of Zantac Lawsuits, But Pipeline Doubts Remain</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Analyst Color

Large Cap

Health Care

Analyst Ratings

Movers

AMGN

RHHBY

VKTX

ZLDPF

Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names

<ul>
<li>IMPACT trial is evaluating the safety and efficacy of pemvidutide in approximately 190 subjects with MASH; top-line efficacy data expected in Q2 2025.</li>
<li>End-of-Phase 2 Meeting for the obesity program with U.S. Food and Drug Administration (FDA) has been scheduled for early November 2024.</li>
<li>Company plans to submit Investigational New Drug (IND) applications for pemvidutide in up to three additional indications beginning in Q4 2024</li>
</ul>

Altimmune Has Completed Patient Enrollment In IMPACT Phase 2B Biopsy-driven Trial Evaluating Pemvidutide In Metabolic Dysfunction-associated Steatohepatitis, Top-line Efficacy Data Expected In Q2 2025

WIIM

Altimmune shares are trading higher after the company presented data from its Phase 2 MRI-based body composition sub-study of pemvidutide in subjects overweight or with obesity.

<a href="https://www.globenewswire.com/news-release/2024/09/10/2943994/0/en/CORRECTION-Altimmune-Presents-Results-of-a-Phase-2-MRI-Based-Body-Composition-Sub-Study-at-60th-Annual-Meeting-of-the-European-Association-for-the-Study-of-Diabetes.html" title="https://www.globenewswire.com/news-release/2024/09/10/2943994/0/en/CORRECTION-Altimmune-Presents-Results-of-a-Phase-2-MRI-Based-Body-Composition-Sub-Study-at-60th-Annual-Meeting-of-the-European-Association-for-the-Study-of-Diabetes.html">https://www.globenewswire.com/news-release/2024/09/10/2943994/0/en/CORRECTION-Altimmune-Presents-Results-of-a-Phase-2-MRI-Based-Body-Composition-Sub-Study-at-60th-Annual-Meeting-of-the-European-Association-for-the-Study-of-Diabetes.html</a>

Altimmune Corrects Previous Release; Says Reduction Of Visceral Adipose Tissue (VAT) At Week 48 Adjusted To 28.3% From 25.6%, And Subcutaneous Adipose Tissue Reduction Revised To 19.5% From 20.1%

In an MRI sub-study of 67 subjects from the Phase 2 MOMENTUM obesity trial, 50 of whom were treated with pemvidutide for 48 weeks, the lean loss ratio, defined as the change in lean mass compared to the change in total mass, was&nbsp;21.9%.
Lean mass preservation was greater in subjects aged 60 years and older, in whom the lean loss ratio was only&nbsp;19.9%. In addition to lean mass preservation, there was a preferential reduction of VAT, the adipose tissue associated with cardiovascular risk.
At the 2.4mg dose of pemvidutide, VAT was reduced by&nbsp;25.6%&nbsp;at Week 48 compared to a&nbsp;20.1%&nbsp;loss in subcutaneous adipose tissue.

Altimmune Presents Data From Its Phase 2, MRI-Based Body Composition Sub-study Of Pemvidutide In Subjects With Overweight And Obesity

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) in the last three months.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Altimmune, presenting an average target of $19.25, a high estimate of $25.00, and a low estimate of $12.00. Consistency is reflected as the current average remains at the same level as the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2024/1724349614_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The perception of Altimmune by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Trucchio</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Mayank Mamtani</td>
<td>B. Riley Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Mayank Mamtani</td>
<td>B. Riley Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Yasmeen Rahimi</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Altimmune. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Altimmune compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Altimmune's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Altimmune's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ALT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Altimmune analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Altimmune</h2>
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.
<h3>A Deep Dive into Altimmune's Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Altimmune's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -16.67%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Altimmune's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -492800.0%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Altimmune's ROE excels beyond industry benchmarks, reaching -15.14%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Altimmune's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -13.62%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Altimmune's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Decoding 4 Analyst Evaluations For Altimmune

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) with a Buy and maintains $12 price target.

Price Target

Reiteration

HC Wainwright & Co. Reiterates Buy on Altimmune, Maintains $12 Price Target

B. Riley Securities analyst Mayank Mamtani reiterates Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) with a Buy and maintains $20 price target.

B. Riley Securities Reiterates Buy on Altimmune, Maintains $20 Price Target

Altimmune shares are trading higher. The company reported Q2 financial results.

Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.34) by 2.94 percent. This is a 9.37 percent decrease over losses of $(0.32) per share from the same period last year. The company reported $5.000 thousand in sales this quarter. This is a 16.67 percent decrease over sales of $6.000 thousand the same period last year.

Earnings

Earnings Misses

CORRECTION: Altimmune Q2 2024 GAAP EPS $(0.35) Misses $(0.34) Estimate, Sales $5.000K Down From $6.000K YoY

Shares of Altimmune are trading higher after a NYPost article highlighted a study comparing the company's Pemvidutide to Ozempic.

<a href="https://nypost.com/2024/06/27/lifestyle/weight-loss-drug-pemvidutide-may-be-better-than-ozempic-trial/" title="https://nypost.com/2024/06/27/lifestyle/weight-loss-drug-pemvidutide-may-be-better-than-ozempic-trial/">https://nypost.com/2024/06/27/lifestyle/weight-loss-drug-pemvidutide-may-be-better-than-ozempic-trial/</a>

Trading Ideas

Watching Altimmune; Traders Circulate New York Post Article 'New weight loss drug may be better than Ozempic — here's how'

Altimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) shares are experiencing significant movement lower following the unexpected passing of Richard Eisenstadt, <a href="https://www.benzinga.com/pressreleases/24/06/g39498530/altimmune-mourns-passing-of-chief-financial-officer-richard-eisenstadt">the company&#8217;s chief financial officer. </a>
What To Know: Eisenstadt&#8217;s sudden death has deeply saddened Altimmune, with CEO Vipin K. Garg highlighting his contributions and personal qualities that endeared him to colleagues.
In response to Eisenstadt&#8217;s passing, Altimmune&#8217;s finance and accounting functions are temporarily being managed by the existing team while the company initiates a search for his replacement. This transition period aims to maintain stability amid the loss of a key executive.
Altimmune is a clinical-stage biopharmaceutical firm specializing in next-generation peptide-based therapeutics, notably developing pemvidutide for treating obesity and non-alcoholic steatohepatitis (NASH). The company remains committed to advancing its pipeline despite this unexpected setback.
ALT Price Action: Altimmune shares were down at market close Wednesday by 15.59% at $6.26, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="549" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/26154826/ALT-1024x549.png" alt="" class="wp-image-407261" style="width:538px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/26154826/ALT-1024x549.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/26154826/ALT-300x161.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/26154826/ALT-768x412.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/06/26154826/ALT.png 1080w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
See Also: <a href="https://www.benzinga.com/real-estate/24/06/39511306/this-arizona-city-has-joined-the-car-free-revolution">This Arizona City Has Joined The Car-Free Revolution</a>
Photo: Via Pixabay.

Management

Why Are Altimmune Shares Trading Lower Wednesday?

Altimmune shares are trading lower following the passing of CEO Richard Eisenstadt.

Altimmune Announces Passing Of Chief Financial Officer, Richard Eisenstadt; Eisenstadt's Duties Are Being Assumed And Performed Bt Finance And Accounting Team Until Replacement Is Named

Altimmune Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) shares are trading higher Monday after the company announced data from the 48-week <a href="https://www.benzinga.com/pressreleases/24/06/g39447690/altimmune-presents-data-from-phase-2-momentum-trial-of-pemvidutide-in-obesity-during-oral-presenta">Phase 2 MOMENTUM clinical trial of pemvidutide</a>.
What Happened: Altimmune said it presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide, including the results of a recently completed body composition analysis at the American Diabetes Association&#8217;s 84th Scientific Sessions.
Pemvidutide is the clinical-stage biopharmaceutical company&#8217;s GLP-1/glucagon dual receptor agonist candidate.
The trial enrolled 391 subjects with obesity, or overweight with at least one co-morbidity and without diabetes. At week 48, subjects receiving pemvidutide achieved mean weight losses of&nbsp;10.3%,&nbsp;11.2%,&nbsp;15.6%&nbsp;and&nbsp;2.2%&nbsp;at the 1.2 mg, 1.8 mg, and 2.4 mg doses and placebo, respectively,&nbsp;
&#8220;We&#8217;re pleased with the data presented at ADA that highlight the impressive lean mass preservation achieved with pemvidutide, with only&nbsp;21.9%&nbsp;of weight loss attributable to lean mass,&#8221; said Vipin Garg, president and CEO of Altimmune. 
&#8220;The preservation of lean mass observed in this trial was better than reported historically with diet and exercise programs and greater than what has been publicly reported with other incretin weight loss drugs, where lean mass has accounted for as much as&nbsp;40%&nbsp;of total weight loss.&#8221;
The full MRI-based body composition analysis included 50 subjects who received pemvidutide and showed that subjects in the pemvidutide groups had an average lean mass loss of&nbsp;21.9%&nbsp;with&nbsp;78.1%&nbsp;of weight loss attributable to fat.
See Also: <a href="https://www.benzinga.com/news/24/06/39453524/mcdonalds-alphabet-and-2-other-stocks-insiders-are-selling">McDonald&#8217;s, Alphabet And 2 Other Stocks Insiders Are Selling</a>
<h2 class="wp-block-heading">How To Buy ALT Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Altimmune's case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
ALT Price Action: Altimmune shares were up 13.3% at $7.26 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: 3844328 from Pixabay.

Altimmune Stock Is Rising Monday: What's Driving The Action?

ALNY: 14% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/39453602">Alnylam Pharmaceuticals shares are trading higher after the company announced topline results from its HELIOS-B Phase 3 study of vutrisiran and that it met the primary endpoints and demonstrated statistically significant improvements across all secondary endpoints.</a>
ALT: 20% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/39453064">Altimmune shares are trading higher after the company announced that it presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide at the American Diabetes Association&#39;s 84th Scientific Sessions.</a>
RGLS: 41% &#x7C;&nbsp;<a href="https://www.benzinga.com//node/39453355">Regulus Therapeutics shares are trading higher after the company announced topline results from the third cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD.</a>

ALNY

RGLS

Market-Moving News for June 24th

U.S. stock futures were mostly higher this morning, with the Dow futures gaining around 100 points on Monday.
Shares of RXO, Inc.. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RXO#NYSE">RXO</a>) shares rose sharply in today's pre-market trading after the company inked a definitive agreement to acquire Coyote Logistics from United Parcel Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) <a href="https://www.benzinga.com/markets/equities/24/06/39453065/rxo-to-buy-coyote-logistics-from-ups-in-billion-dollar-deal-whats-on-the-move">for $1.025 billion in cash.</a>
As per the terms, the transaction disclosed on Sunday will be financed through a combination of equity and debt, including a $300 million equity investment from MFN Partners and a $250 million equity investment from Orbis Investments, both significant shareholders of RXO.
RXO shares jumped 13.3% to $22.90 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Alnylam Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) shares gained 38.8% to $230.00 in pre-market trading after announcing topline results from its HELIOS-B Phase 3 study of vutrisiran.</li>
<li>Altimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) shares gained 10.9% to $7.10 in pre-market trading after the company announced that it presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide at the American Diabetes Association&#8217;s 84th Scientific Sessions.</li>
<li>Clover Health Investments, Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) gained 9.6% to $1.37 in pre-market trading after gaining over 21% on Friday.</li>
<li>argenx SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) shares gained 9.9% to $433.52 in pre-market trading after the company announced the FDA approval of VYVGART Hytrulo for chronic inflammatory demyelinating polyneuropathy.</li>
<li>Intellia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) shares gained 9.5% to $26.51 in pre-market trading.</li>
<li>Pharming Group N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAR#NASDAQ">PHAR</a>) shares gained 8.1% to $7.86 in pre-market trading after declining 8% on Friday.</li>
<li>Ionis Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>) shares gained 5.2% to $44.01 in pre-market trading.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/markets/equities/24/06/39450365/investor-optimism-improves-despite-stocks-ending-mixed-on-friday-s-p-500-closes-lower-with-nvidi">Investor Optimism Improves Despite Stocks Ending Mixed On Friday: S&amp;P 500 Closes Lower With Nvidia Dropping Over 3%, Dow Jones Ends Marginally Higher</a>
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>

Pre-Market Outlook

Markets

ARGX

CLOV

IONS

NTLA

PHAR

RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Terns stock jumps as weight loss drug succeeds in early trial

Altimmune spikes after presenting data for obesity drug

Altimmune (ALT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jonathan Wolleben from JMP ...

Buy Rating Affirmed for Altimmune on Pemvidutide's Positive Trial Data and Strategic Advancements

Altimmune: Updated Data Supports Pemvidutide's 'Market Disruptor' Prospects

JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Altimmune (ALT – Research Report) today and set a price target of $24.00. Jonat...

Buy Rating Affirmed for Altimmune: Promising Pemvidutide Trial Progress and Market Differentiation

Roche sees Carmot obesity drugs' potential peak sales at $3.6B+: report

Lilly looking to test Zepbound as health maintenance drug: report

Consider Buying Potential Takeover Target Altimmune

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Abbott Laboratories (ABT – Research Report), Altim...

Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Altimmune (ALT) and Steris (STE)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Altimmune (ALT – Research Report), Hansa Biopharma A...

Analysts Are Bullish on Top Healthcare Stocks: Altimmune (ALT), Hansa Biopharma AB (SE:HNSA)

GPCR

NONOF

TERN

VRDN

Press Releases

Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology

Legal

ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Altimmune, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes

Sprout Social, Altimmune, Equinix, and Globe Life Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes

Comments

Altimmune

Notizie

Ultime notizie per Altimmune (NASDAQ:ALT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO